Satsuma Pharmaceuticals, Inc.

In contrast to the prodigious novel approval counts of 2023, the US FDA started the new year in a more abstemious fashion. After approving Ligand Pharmaceuticals, Inc. ’s new molecular entity Zelsuvm

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. SNBL To Pay 28% Premium To Re-Acquire S

With investors closely watching how biopharmaceutical companies are spending the cash they have on hand so that they do not run out of money in a tough fundraising environment, even firms with revenue

Third quarter biopharmaceutical start-up financings fell 23% from the second quarter, but large individual company financings continue to stand out, including Century Therapeutics with a $250m serie